Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | KAT7 | O95251 | 10/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 10/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | KAT6B | Q8WYB5 | 4/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 3/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420281 | 0.84 | L3MBTL1 (0.39) | MAPT | |
| SCHEMBL15420605 | 0.84 | HDAC1 (0.41) | HDAC1HDAC6GAAMAPTCHRM1 | |
| SCHEMBL12988721 | 0.79 | CHRM1 (0.42) | KAT7MAPTKAT5CHRM1HRH3 | |
| SCHEMBL12988723 | 0.79 | CHRM1 (0.42) | KAT7MAPTKAT5CHRM1HRH3 | |
| SCHEMBL12988718 | 0.79 | CHRM1 (0.42) | KAT7MAPTKAT5CHRM1HRH3 | |
| SCHEMBL15420040 | 0.77 | CHRM1 (0.36) | HCRTR2CHRM1HRH3 | |
| SCHEMBL15441641 | 0.77 | CHRM1 (0.36) | HCRTR2CHRM1HRH3 | |
| SCHEMBL21795658 | 0.77 | HDAC1 (0.39) | CA12CA1CA2CA9HDAC1 | |
| SCHEMBL15420687 | 0.77 | P2RX3 (0.41) | HCRTR2 | |
| SCHEMBL15419860 | 0.77 | P2RX3 (0.41) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | CA12 3894/4885CA1 1931/4885CA2 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.